ClinicalTrials.gg
CompletedNCT04888689Updated Feb 12, 2025

Holter of Movement in Patients with Multiple Sclerosis in Controlled Environment.

An interventional study of Actimyo° and IMU in Multiple Sclerosis, sponsored by Laurent Servais. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Laurent Servais · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 157 studies in Multiple Sclerosis with a site in Belgium — 14 open to participants now, 30 under way, 10 of them phase 3. Multiple Sclerosis · Belgium.

Enrollment
117th of 132
21 · median 163
Started
2021
with 7 others
No phase
47 of 157
5 open now
Registered
120th of 157
by date

Among the 157 studies in Multiple Sclerosis with a site in Belgium, this one is the 117th largest by enrollment of the 132 interventional ones that give a count, is one of 8 that started in 2021, is one of 47 with no phase, and was the 120th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

14 of the 157 studies in Multiple Sclerosis with a site in Belgium are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 157 studies in Multiple Sclerosis with a site in Belgium, or all of them as a file.
02

Study summary

ActiSEP is a multicentric academic study. Ambulant patients with multiple sclerosis may be included on a voluntary basis. We plan to include a group of approximately 20 patients with MS.

This study include a unique evaluation in the laboratory of analysis of human movement. A set of tasks will be performed by patients wearing of two magneto-inertial sensors.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Actimyo
  • Accelerometry
  • Motion laboratory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed MS diagnosis,
  • Over 18 years old,
  • Ambulant patients,
  • Signed ,
  • No clinical and / or radiological relapse within 3 months.

Exclusion criteria

Exclusion Criteria:

  • Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.
  • Any other previous or present pathology having an impact on motor function.
  • Recent surgery or trauma (less than 6 months) in the upper or lower limbs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    MS patients

    Ambulant patients with multiple sclerosis

    Device: Actimyo° · Device: IMU

Interventions

  • DeviceActimyo°

    Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.

  • DeviceIMU

    IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope. These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes.

06

What researchers measure

Primary outcomes

  1. 95th centile of stride velocity

    95th centile of stride velocity obtained with magneto-inertial sensors and a motion capture device (meter/second).

    Time frame: One day

  2. 50th centile of stride velocity

    50th centile of stride velocity obtained with magneto-inertial sensors and a motion capture device (meter/second).

    Time frame: One day

  3. 95th centile of stride length

    95th centile of stride length obtained with magneto-inertial sensors and a motion capture device (meter).

    Time frame: One day

  4. 50th centile of stride length

    50th centile of stride length obtained with magneto-inertial sensors and a motion capture device (meter).

    Time frame: One day

  5. Stance phase time

    Stance time over full stride time for each foot obtained with magneto-inertial sensors and a motion capture device (percentage).

    Time frame: One day

07

Study locations

1 site
  • Centre Hospitalier Régional de la Citadelle
    Liège, 4000, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Sep 2021, 7 months.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 7 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
May 17, 2021
StartActual
Feb 4, 2021
Primary completionActual
Sep 30, 2021
CompletionActual
Sep 30, 2021
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04888689
Lead sponsor
Laurent Servais
Collaborators
SYSNAV, Centre Hospitalier Régional de la Citadelle
Responsible party
Laurent Servais (Principal investigator, Centre Hospitalier Universitaire de Liege) — Sponsor-investigator
First posted
May 17, 2021
Start date
Feb 4, 2021
Primary completion
Sep 30, 2021
Completion
Sep 30, 2021
Last update
Feb 12, 2025

Study contacts

Margaux Poleur, MD
principal investigator · CHR Citadelle-CHU liège

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion